# OnQuality Pharmaceuticals

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/onquality-pharmaceuticals

- Industry: Pharmaceuticals
- Headquarters: Shanghai, China
- Website: www.onqualityrx.com
- Total disclosed funding: $35M
- Latest round: Series A (Mar 31, 2021)
- Investors on record: 6

## About

OnQuality Pharmaceuticals LLC focuses on developing innovative cancer supportive care treatments to mitigate severe side effects of cancer therapies, ensuring patients can maintain their treatment regimens and enhance their quality of life.OnQuality Pharmaceuticals LLC, founded in 2018 and headquartered in Shanghai, China, specializes in targeted cancer supportive care solutions. The company aims to fill significant gaps in supportive oncology treatments. The founders include Hong Tang, Jie Luo, and Shiyi Zhang. In March 2021, OnQuality raised USD 20.00 mn in Series A funding from investors including BioTrack Capital, CASH Capital, Frees Fund, MPC, Shiyu Capital, and Sinovation Ventures. This round represented the total amount raised by the company to date, which is USD 20.00 mn.OnQuality Pharmaceuticals specializes in developing targeted cancer supportive care treatments designed to alleviate the intolerable side effects associated with specific cancer therapies. Their core offerings focus on preventing and managing dose-limiting toxicities that arise from anti-cancer medications, thereby enabling patients to maintain their treatment regimens and improve their quality of life. The company’s product pipeline addresses significant treatment gaps in the oncology space, particularly in the realm of supportive care, which has historically received less attention within pharmaceutical development. OnQuality Pharmaceuticals aims to serve a broad range of oncology patients, healthcare providers, and institutions in both the United States and selected international markets, enhancing patient outcomes through its innovative therapeutic solutions.OnQuality Pharmaceuticals operates on a transactional structure that involves direct partnerships with healthcare providers and institutions to facilitate the distribution of its supportive care products. The revenue model includes B2B agreements with hospitals and clinics, wherein these healthcare entities incorporate OnQuality's treatments into their patient care protocols. Pricing plans are structured around individual product offerings, which are tailored to specific patient needs and healthcare settings. As the company continues to expand its product line, it aims to establish strategic alliances that enhance market penetration and increase accessibility to its innovative solutions, thereby driving revenue growth through both existing and new client relationships.OnQuality Pharmaceuticals plans to utilize the USD 20.00 mn raised in Series A funding to support the development of its drug candidates and to conduct a Phase II clinical trial for its compound OQL011. The company is focused on launching new products designed specifically for oncology supportive care and aims to expand its market presence in the United States and select international regions. By implementing these strategies, OnQuality Pharmaceuticals seeks to strengthen its position in the oncology market and enhance patient care outcomes.

## Funding rounds

- Series A, Mar 31, 2021, $20M — Sinovation Ventures, CASH Capital, Frees Fund, MPC, BioTrack Capital, Shiyu Capital
- Series A, Oct 28, 2019, $15M — CASH Capital, MPC, BioTrack Capital

## Investors

- CASH Capital (https://capitalatlas.ai/funds/cash-capital) — Series A
- MPC — Series A
- BioTrack Capital (https://capitalatlas.ai/funds/biotrack-capital) — Series A
- Sinovation Ventures (https://capitalatlas.ai/funds/sinovation-ventures) — Series A
- Frees Fund (https://capitalatlas.ai/funds/frees-fund) — Series A
- Shiyu Capital (https://capitalatlas.ai/funds/shiyu-capital) — Series A